Cytoreductive Surgery for Melanoma

Surgical Oncology Clinics of North America

Volumn 16, Issue 3, 2007, Pages 683-693

  McLoughlin, James M ^a   Zager, Jonathan S ^b   Sondak, Vernon K ^b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BCG VACCINE; CANVAXIN; CORTICOSTEROID; INTERFERON; IODINE 131; MELPHALAN; PLACEBO; RHENIUM 186; YTTRIUM 90;

ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DOSE RESPONSE; DRUG MEGADOSE; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; MELANOMA; METASTASIS; NONHUMAN; REVIEW; THROMBOCYTOPENIA;

CHEMOTHERAPY, ADJUVANT; HUMANS; IMMUNOTHERAPY; MELANOMA; NEOADJUVANT THERAPY;

EID: 34250851890     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2007.04.007     Document Type: Review

References (46)

1. Ollila D.W., Essner R., Wanek L.A., et al. Surgical resection for melanoma metastatic to the gastrointestinal tract. Arch Surg 131 9 (1996) 975-980
2. Haigh P.I., Essner R., Wardlaw J.C., et al. Long-term survival after complete resection of melanoma metastatic to the adrenal gland. Ann Surg Oncol 6 7 (1999) 633-639
3. McLoughlin J.M., Zager J.S., Sloan A.S., et al. Melanoma: surgical approach to metastatic disease. In: Silberman H., and Silberman A.W. (Eds). Principles and practice of surgical oncology: a multidisciplinary approach to difficult problems. 2nd edition (2007), Lippincott Williams & Williams, Baltimore (MD)
4. Essner R., Lee J.H., Wanek L.A., et al. Contemporary surgical treatment of advanced-stage melanoma. Arch Surg 139 9 (2004) 961-966 [discussion: 966-7]
5. Sondak V.K., Liu P.Y., Warnecke J., et al. Surgical resection for stage IV melanoma: a Southwest Oncology Group Trial (S9430). Proc Amer Soc Clin Oncol 24 (2006) 457S
6. Fogarty G.B., and Tartaguia C. The utility of magnetic resonance imaging in the detection of brain metastases in the staging of cutaneous melanoma. Clin Oncol (R Coll Radiol) 18 4 (2006) 360-362
7. Brady M.S., Akhurst T., Spanknebel K., et al. Utility of preoperative [18]F-fluorodeoxyglucose-positron emission tomography scanning in high-risk melanoma patients. Ann Surg Oncol 13 4 (2006) 525-532
8. Pawlik T.M., Zorzi D., Abdalla E.K., et al. Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol 13 5 (2006) 712-720
9. Agrawal S., Yao T.J., and Coit D.G. Surgery for melanoma metastatic to the gastrointestinal tract. Ann Surg Oncol 6 4 (1999) 336-344
10. Mandybur T.I. Intracranial hemorrhage caused by metastatic tumors. Neurology 27 7 (1977) 650-655
11. Tran P., Fogarty G., Phillips C., et al. Worthwhile palliation with surgery for symptomatic haemorrhage from brain metastasis. ANZ J Surg 75 5 (2005) 366
12. Spitler L.E., Grossbard M.L., Ernstoff M.S., et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 18 8 (2000) 1614-1621
13. Hsueh E.C., Essner R., Foshag L.J., et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 20 23 (2002) 4549-4554
14. Wornom III I.L., Smith J.W., Soong S.J., et al. Surgery as palliative treatment for distant metastases of melanoma. Ann Surg 204 2 (1986) 181-185
15. Morton D.L., Mozzillo N., Thompson J.F., et al. An international randomized, double-blind, phase 3 study of the specific active immunotherapy agent, onamelatucel-L (Canvaxin™), compared to placebo as a post-surgical adjuvant in AJCC stage IV melanoma. Ann Surg Oncol 13 Suppl 2 (2006) 5
16. Bezjak A., Adam J., Barton R., et al. Symptom response after palliative radiotherapy for patients with brain metastases. Eur J Cancer 38 4 (2002) 487-496
17. Bezjak A., Adam J., Panzarella T., et al. Radiotherapy for brain metastases: defining palliative response. Radiother Oncol 61 1 (2001) 71-76
18. Fife K.M., Colman M.H., Stevens G.N., et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 22 7 (2004) 1293-1300
19. Fraker D.L. Management of in-transit melanoma of the extremity with isolated limb perfusion. Curr Treat Options Oncol 5 3 (2004) 173-184
20. Noorda E.M., Vrouenraets B.C., Nieweg O.E., et al. Safety and efficacy of isolated limb perfusion in elderly melanoma patients. Ann Surg Oncol 9 10 (2002) 968-974
21. Takkenberg R.B., Vrouenraets B.C., van Geel A.N., et al. Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients. J Surg Oncol 91 2 (2005) 107-111
22. Fraker D.L., Alexander H.R., Andrich M., et al. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor. Cancer J Sci Am 1 2 (1995) 122-130
23. McCahill L.E., Smith D.D., Borneman T., et al. A prospective evaluation of palliative outcomes for surgery of advanced malignancies. Ann Surg Oncol 10 6 (2003) 654-663
24. Petersen R.P., Hanish S.I., Haney J.C., et al. Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma. J Thorac Cardiovasc Surg 133 1 (2007) 104-110
25. Mukherji B., Nashed A.L., Guha A., et al. Regulation of cellular immune response against autologous human melanoma. II. Mechanism of induction and specificity of suppression. J Immunol 136 5 (1986) 1893-1898
26. Mukherji B., Wilhelm S.A., Guha A., et al. Regulation of cellular immune response against autologous human melanoma. I. Evidence for cell-mediated suppression of in vitro cytotoxic immune response. J Immunol 136 5 (1986) 1888-1892
27. Chakraborty N.G., Twardzik D.R., Sivanandham M., et al. Autologous melanoma-induced activation of regulatory T cells that suppress cytotoxic response. J Immunol 145 7 (1990) 2359-2364
28. Hsueh E.C., Nathanson L., Foshag L.J., et al. Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases. Cancer 85 10 (1999) 2160-2169
29. Rabinovich G.A., Gabrilovich D., and Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25 (2007) 267-296
30. Gajewski T.F. Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. Clin Cancer Res 12 7 (2006) 2326S-2330S
31. Sakatsume M., Harada Y., Ling X., et al. Autoreactive T-cell clones which suppress cytotoxic T cell responses. Int Immunol 3 4 (1991) 377-384
32. Moiseyenko V.M., Danilov A.O., Baldueva I.A., et al. Phase I/II trial of gene therapy with autologous tumor cells modified with tag7/PGRP-S gene in patients with disseminated solid tumors: miscellaneous tumors. Ann Oncol 16 1 (2005) 162-168
33. Emms S.G. Anal sac tumours of the dog and their response to cytoreductive surgery and chemotherapy. Aust Vet J 83 6 (2005) 340-343
34. Janssen M.L., Pels W., Massuger L.F., et al. Intraperitoneal radioimmunotherapy in an ovarian carcinoma mouse model: effect of the radionuclide. Int J Gynecol Cancer 13 5 (2003) 607-613
35. Jarnicki A.G., Lysaght J., Todryk S., et al. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol 177 2 (2006) 896-904
36. Uno K., Mitsuishi Y., Tanigawa M., et al. A series of immune responses leading to the induction of T cell IL-12/IL-18 responsiveness in patients with relatively large tumor burdens. Cancer Immunol Immunother 52 1 (2003) 33-40
37. Yamshchikov G.V., Barnd D.L., Eastham S., et al. Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients. Int J Cancer 92 5 (2001) 703-711
38. Shu S., Cochran A.J., Huang R.R., et al. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy. Cancer Metastasis Rev 25 2 (2006) 233-242
39. Vuylsteke R.J., Molenkamp B.G., van Leeuwen P.A., et al. Tumor-specific CD8+ T cell reactivity in the sentinel lymph node of GM-CSF-treated stage I melanoma patients is associated with high myeloid dendritic cell content. Clin Cancer Res 12 9 (2006) 2826-2833
40. Faries M.B., and Morton D.L. Therapeutic vaccines for melanoma: current status. BioDrugs 19 4 (2005) 247-260
41. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14 1 (1996) 7-17
42. Kirkwood J.M., Ibrahim J.G., Sondak V.K., et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18 12 (2000) 2444-2458
43. Kirkwood J.M., Ibrahim J.G., Sosman J.A., et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19 9 (2001) 2370-2380
44. Moschos S.J., Edington H.D., Land S.R., et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 24 19 (2006) 3164-3171
45. Buzaid A.C., Colome M., Bedikian A., et al. Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases. Melanoma Res 8 6 (1998) 549-556
46. Lewis K.D., Robinson W.A., McCarter M., et al. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma. J Clin Oncol 24 19 (2006) 3157-3163